In fact, reports show that the numbers doubled between 2003 and 2017 for cancer spreading to distant parts of the body, going from 4% to 8% according to the U.S. Center for Disease Control (CDC) and Prevention.
Men are dying because of increased metastatic disease and Stage 4 cancer, with obvious racial differences being reported by the CDC.
According to researchers, five-year survival for distant state prostate cancers were higher among Asian/Pacific Islanders (42%), followed by Hispanics (37%), American Indian/Alaska Natives (32%), Black men (32%), and white men (29%).
Being aware of and understanding these numbers, as well as staying atop of the continued research helps educate men about prostate cancer, which can lead to more talks between the patient and provider about the decision to utilize prostate cancer screening.
The key is about being smarter and knowing who to treat and who not to treat. Men with low-risk cases may not require PSA screening as an option, but the open discussion with a trusted and knowledgeable medical provider will help them in their decision-making.
The reversal of the PA screening recommendation did not occur until 2018, so it will take a couple of years before the plateau and decrease in Stage 4 cases will be noticeable.
Further knowledge of these cancer rates will greatly help with guiding treatment and managing the planning of survival care. Staying informed and educated is key.
Sourced by HealthDay News